Canaccord Genuity set a $16.00 target price on Halozyme Therapeutics, Inc. (NASDAQ:HALO) in a research note issued to investors on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the stock. BidaskClub cut shares of Halozyme Therapeutics from a buy rating to a hold rating in a research report on Saturday, July 1st. Barclays PLC reiterated an overweight rating and issued a $16.00 price target on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. ValuEngine upgraded shares of Halozyme Therapeutics from a sell rating to a hold rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a sell rating to a hold rating in a research report on Friday, May 12th. Finally, BMO Capital Markets assumed coverage on shares of Halozyme Therapeutics in a research report on Monday, April 17th. They issued a market perform rating and a $14.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $14.84.

Halozyme Therapeutics (HALO) opened at 12.91 on Wednesday. Halozyme Therapeutics has a 12-month low of $8.18 and a 12-month high of $15.20. The stock’s market capitalization is $1.66 billion. The firm’s 50-day moving average is $13.41 and its 200 day moving average is $13.05.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.01. The business had revenue of $29.60 million for the quarter, compared to analysts’ expectations of $30.79 million. During the same quarter in the previous year, the business posted ($0.16) EPS. The company’s quarterly revenue was down 30.4% compared to the same quarter last year. Equities research analysts anticipate that Halozyme Therapeutics will post ($0.98) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Analysts Give Halozyme Therapeutics, Inc. (NASDAQ:HALO) a $16.00 Price Target” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/canaccord-genuity-analysts-give-halozyme-therapeutics-inc-nasdaqhalo-a-16-00-price-target/1462352.html.

Hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new stake in Halozyme Therapeutics during the first quarter valued at about $122,000. Stifel Financial Corp bought a new stake in Halozyme Therapeutics during the first quarter valued at about $187,000. Karp Capital Management Corp bought a new stake in Halozyme Therapeutics during the first quarter valued at about $188,000. Parametrica Management Ltd bought a new stake in Halozyme Therapeutics during the first quarter valued at about $212,000. Finally, Highbridge Capital Management LLC bought a new stake in Halozyme Therapeutics during the fourth quarter valued at about $215,000. Hedge funds and other institutional investors own 81.36% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.